<DOC>
	<DOCNO>NCT00949325</DOCNO>
	<brief_summary>The purpose study identify safe dose regimen combination Torisel liposomal doxorubicin patient recurrent sarcoma . A secondary purpose study determine effective combination treatment recurrent sarcoma .</brief_summary>
	<brief_title>Safety Efficacy Study Torisel Liposomal Doxorubicin Patients With Recurrent Sarcoma</brief_title>
	<detailed_description>The effectiveness treatment recurrent sarcomas quite limited . One hypothesis explain refractory nature recurrent sarcoma existence chemotherapy-resistant sarcoma stem cell .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically confirm sarcoma recurrent refractory conventional treatment Measurable disease RECIST criterion ECOG performance status &lt; 2 ( Lansky/Karnofsky &gt; 60 % child ) Life expectancy great 3 month Adequate organ function absolute neutrophil count least 1,500 platelet least 100,000 bilirubin less 1.5 x upper limit normal AST ALT le 2.5 x upper limit normal creatinine le 1.5 x upper limit normal OR creatinine clearance least 60 ml/min/1.73 m2 fast serum cholesterol le 350 fasting serum triglycerides less 400 PT INR le 1.3 x upper limit normal normal urinalysis Ability understand sign inform consent document Prior chemotherapy radiotherapy within 3 week enter study ( 6 week nitrosoureas mitomycin C ) Prior treatment tyrosine kinase inhibitor within 10 day enter study History pulmonary hypertension pneumonitis Patients may receive investigational agent Prior therapy rapamycin , rapamycin analogue , tacrolimus Uncontrolled brain metastasis History grade 3 4 hypersensitivity macrolide antibiotic Concurrent treatment immunosuppressive agent stable ( 2 week ) dose corticosteroid Uncontrolled intercurrent illness Pregnancy breast feed HIVpositive patient combination antiretroviral therapy Grade 3 4 proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>leiomyosarcoma</keyword>
	<keyword>Ewing 's sarcoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>liposarcoma</keyword>
	<keyword>malignant fibrous histiocytoma</keyword>
	<keyword>malignant peripheral nerve sheath tumor</keyword>
	<keyword>pleiomorphic sarcoma</keyword>
	<keyword>spindle cell sarcoma</keyword>
	<keyword>synovial sarcoma</keyword>
	<keyword>cancer stem cell</keyword>
</DOC>